DNA, thymidylate synthase, dihydrofolate reductase and related intracellular macromolecules

This target entry refers to a collective group of intracellular macromolecules and enzymes central to the folate metabolic pathway, which is essential for the de novo synthesis of purine and pyrimidine nucleotides (Source: PubChem CID 135410875). The primary components include Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT), as well as DNA itself (Source: FDA Alimta Label). These enzymes catalyze the production of thymidine and purine nucleotides; their inhibition leads to a depletion of nucleotide pools, halting DNA replication and inducing apoptosis, a process often termed thymineless death (Source: StatPearls, Antifolates). This multi-target approach is the pharmacological basis for antifolate chemotherapy agents like pemetrexed, which are designed to disrupt multiple points in the nucleotide synthesis pathway to provide more robust inhibition of tumor growth compared to single-target inhibitors (Source: NIH National Cancer Institute). Clinical use of drugs hitting this target profile typically requires vitamin supplementation to mitigate severe hematologic and gastrointestinal toxicities associated with the disruption of these essential cellular processes.

Other names

Multi-targeted antifolate targetsFolate metabolism enzymesPemetrexed target complexTS/DHFR/GARFT

Simultaneous inhibition of multiple folate-dependent enzymes, primarily thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which prevents the de novo synthesis of thymidine and purine nucleotides required for DNA and RNA replication.